TCN1

Across TCGA pan-cancer cohorts, TCN1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TCN1’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where TCN1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TCN1 is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

PDAC, COAD, and CCRCC are the cancer types where TCN1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TCN1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	III,IV	+1.287	<.001	8	view →
COAD	All	All	+0.925	.048	4	view →
CCRCC	All	All	+0.839	.007	4	view →
LUAD	Female	III,IV	−0.878	.001	3	view →
HNSC	All	II,III,IV	−0.423	.044	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TCN1–PDAC

Open the PDAC breakdown →